期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子靶向治疗胃肠间质瘤的进展 被引量：8

原文传递
导出
摘要 胃肠间质瘤（gastrointestinal stromal tumor，GIST）是最常见的胃肠道间叶源性肿瘤。其发病率约占消化道肿瘤的1％，年发病率为15／100万，发病中位年龄约为60岁。约有20％～30％的患者是GIST高度侵袭危险人群。由于GIST对常规放疗及化疗均极不敏感，既往手术是其主要且惟一有效的治疗手段，然而高危GIST患者极易复发。以前对于GIST无法切除或转移复发患者缺乏良好对策,
作者 张云 曹晖
机构地区 上海交通大学医学院附属仁济医院普通外科
出处 《中华消化外科杂志》 CAS CSCD 2009年第6期478-480,共3页 Chinese Journal of Digestive Surgery
关键词 分子靶向治疗 胃肠间质瘤 GIST 间叶源性肿瘤 年发病率 转移复发 消化道肿瘤 中位年龄
分类号 R735 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer,2005,103(4) :821 -829.
  • 2Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med,2002,347(7) :472 -480.
  • 3Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase Ⅱ trial of standard versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol,2008,26 (4) :620 -625.
  • 4Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase Ⅲ study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol,2007,25(9) :1107 -1113.
  • 5Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet, 2004,364 ( 9440 ) : 1127 - 1134.
  • 6Blanke CD, Rankin C, Demetri GD, et al. Phase Ⅲ randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 2008,26(4) :626 -632.
  • 7Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol,2007,14( 1 ) :14 -24.
  • 8Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinlb mesylate after resection of localised, primary gastrointestinal stromal turnout: a randomised, double-blind, placebo-controlled trial. Lancet,2009,373 (9669) : 1097 - 1104.
  • 9Van Glabbeke M, Verweij J. Casali PG, et al. Initial and late resistance to imatlnib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group- Australasian Gastrointestinal Trials Group study. J Clin Oncol, 2005,23 (24) :5795 - 5804.
  • 10Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol,2003,21 ( 23 ) :4342 - 4349.

同被引文献61

引证文献8

二级引证文献23

中华消化外科杂志
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部